Frontiers in Immunology Paper Discloses Promising New Insights into CAR T Cell Efficacy for Cancer Therapies
The paper describes innovative research conducted at Kings College London under the auspices of Dr. John Maher, in collaboration with Leucid Bio, using LUMICKS' z-Movi Cell Avidity Analyzer.
- The paper describes innovative research conducted at Kings College London under the auspices of Dr. John Maher, in collaboration with Leucid Bio, using LUMICKS' z-Movi Cell Avidity Analyzer.
- This new research suggests that adding a second targeting receptor to CAR T cells enhances their ability to target cancer cells and shows promise to improve immunotherapies for cancer in pre-clinical models.
- New insights obtained using cell avidity measurements can really help improve the way we design cell therapies."
- Similarly, the z-Movi Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells.